GE Scientists in Technology “Relay Race” Against Cancer

  GE Scientists in Technology “Relay Race” Against Cancer

  *GE technologies being developed to impact every stage of cancer patient
    care from screening to treatment and monitoring
  *Earlier detection, more precise diagnosis, and enabling more effective
    treatments and monitoring all key goals in the race to defeat cancer

Business Wire

NISKAYUNA, N.Y. -- May 20, 2013

To commemorate National Cancer Research Month, a team of scientists from GE
Global Research, the technology development arm of the General Electric Co.
(NYSE: GE), are joined together in a technology “relay race” against cancer.
They collectively are driving technologies across the entire continuum of
cancer care with the end-goal of improving patient outcomes.

A team of scientists from GE Global Research who are developing technology to
improve cancer care. T ...

A team of scientists from GE Global Research who are developing technology to
improve cancer care. Their work is featured in a new video, the "Technology
Race Against Cancer". (Photo: Business Wire)

The research and development activities of GE scientists are highlighted in a
special video that walks through every stage of cancer patient care from
screening, diagnosis, biopsy and staging to treatment, monitoring and
remission. During the video, Fiona Ginty, a principal scientist at GE Global
Research, summed up the multi-disciplinary team effort underway inside GE’s
research labs.

Ginty stated, “There are many stages to the patient’s treatment journey. We
have amazing teams here; people from all backgrounds, from biology, chemistry,
engineering, optical sciences you name it. A team like that is what is needed
in order to create new technology and new solutions for patients.”

Cindy Davis, Therapy Platform Leader at GE Global Research, stated, “We have
been looking at cancer from a disease perspective rather than a technology
perspective and how do we pull in the different technologies that are needed
at each different stage of the patient’s journey.”

According to the World Cancer Research Fund, an estimated 21 million cancer
cases will occur worldwide in 2013 alone. At each stage of the patient’s
journey, GE scientists are developing new technologies to help more patients
emerge cancer free.

Screening – Developing a digital mammography system to enable a 3D
representation of a woman’s breast to potentially help clinicians detect
cancer earlier.

Diagnosis – Work on a new high-risk screening platform using Magnetic
Resonance Imaging (MRI), with the goal of providing a more reliable of way of
diagnosing women who are at a greater risk of getting cancer early.

Biopsy – Driving advancements in molecular pathology to allow pathologists to
see inside a tumor in new ways. GE’s technology is being developed to
highlight more than 60 disease markers in a single tissue sample. Standard
samples viewed today typically show only one or two markers. These new
insights could help determine if a cancer is more or less aggressive and what
treatments a patient might respond best to.

Staging – New methods being developed using Positron Emission Technology (PET)
imaging to more precisely measure the progress of how a patient is responding
to treatment. The goal is to shrink the time it takes to monitor how
treatments are going from months to weeks.

Treatment –Exploring ways to bring multiple healthcare technologies together
to combat cancer more effectively. GE Global Research has an Interventional &
Therapy Lab that is combining X-Ray, Ultrasound, software and analytics and
other healthcare technologies to improve how cancer is treated. In addition,
GE scientists are developing better tools to support emerging cell therapies
being developed and used to treat cancer.

Monitoring – Developing contrast agents for MRI that will allow metabolic
activity in the body to be observed in real-time. This could enable doctors to
identify the aggressiveness of a tumor and impact the course of treatments.

Remission – Focused on new technologies that can monitor a patient after they
have been treated and determine if a cancer has come back much earlier. This
could help make the treatment of cancer more manageable.

At the end of the video, Ashwin Wagadarikar, an electrical engineer in the
Functional Imaging Lab, concluded, stating, “This race, like any other race,
will have a finish line.”

The relay race is part of GE’s commitment to accelerate cancer innovation by
investing $1 billion in cancer technology research and development as well as
improve care for 10 million cancer patients around the world by 2020. For
additional details can be found at healthymagination.com/cancer.

About GE Global Research

GE Global Research is the hub of technology development for all of GE's
businesses. Our scientists and engineers redefine what’s possible, drive
growth for our businesses, and find answers to some of the world’s toughest
problems.

We innovate 24 hours a day, with sites in Niskayuna, New York; San Ramon,
California; Bangalore, India; Shanghai, China; Munich, Germany; and Rio de
Janeiro, Brazil.

Visit GE Global Research on the web at www.ge.com/research. Connect with our
technologists at http://edisonsdesk.com and http://twitter.com/edisonsdesk.

**The concepts and technology in development mentioned in the announcement
and/or video represent ongoing research and development efforts. These
concepts and technologies are not products and may never become products. Not
for sale. Not CE marked. Not cleared, approved or authorized by the U.S. FDA
or other national regulatory authorities for commercial availability.

WAVE & In Cell Analyzer Products are for research use only, not for use in
diagnostic procedures, and are sold subject to the terms and conditions of
sale of the company within GE Healthcare which supplies them.

Photos/Multimedia Gallery Available:
http://www.businesswire.com/multimedia/home/20130520005193/en/

Multimedia
Available:http://www.businesswire.com/cgi-bin/mmg.cgi?eid=50635615&lang=en

Contact:

GE Media:
Todd Alhart, 518-387-7914
todd.alhart@ge.com